| 17 ديسمبر 2025 أُودع في 19 ديسمبر 2025 | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) Common Stock | مُتصرَّف فيه (D) | 148,153 | 11.00 | 1,629,683 مشتق: الأسهم × سعر السهم. القيمة الدقيقة 1629683.00. | 0 | غير مباشرة (I) See Footnote | لا | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| فتح الإيداع 0001104659-25-123156 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 17 ديسمبر 2025 أُودع في 19 ديسمبر 2025 | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) ورقة مالية مشتقة: Prefunded Warrants — الأصل الأساسي Common Stock (433,962) — سعر الممارسة 0.0001 | مُتصرَّف فيه (D) | 433,962 | 10.999 | 4,773,148.038 مشتق: الأسهم × سعر السهم. القيمة الدقيقة 4773148.038. | 0 | غير مباشرة (I) See Footnote | لا | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| فتح الإيداع 0001104659-25-123156 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 17 ديسمبر 2025 أُودع في 19 ديسمبر 2025 | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) ورقة مالية مشتقة: Series A Common Stock Purchase Warrants — الأصل الأساسي Common Stock (117,019) — سعر الممارسة 8.16 | مُتصرَّف فيه (D) | 117,019 | 4.71 | 551,159.49 مشتق: الأسهم × سعر السهم. القيمة الدقيقة 551159.49. | 0 | غير مباشرة (I) See Footnote | لا | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| فتح الإيداع 0001104659-25-123156 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 17 ديسمبر 2025 أُودع في 19 ديسمبر 2025 | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) ورقة مالية مشتقة: Series C Common Stock Purchase Warrants — الأصل الأساسي Common Stock (117,019) — سعر الممارسة 8.16 | مُتصرَّف فيه (D) | 117,019 | 4.71 | 551,159.49 مشتق: الأسهم × سعر السهم. القيمة الدقيقة 551159.49. | 0 | غير مباشرة (I) See Footnote | لا | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| فتح الإيداع 0001104659-25-123156 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 17 ديسمبر 2025 أُودع في 19 ديسمبر 2025 | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) ورقة مالية مشتقة: Amended Series A Common Stock Purchase Warrants — الأصل الأساسي Common Stock (158,531) — سعر الممارسة 0.01 | مُتصرَّف فيه (D) | 158,531 | 10.99 | 1,742,255.69 مشتق: الأسهم × سعر السهم. القيمة الدقيقة 1742255.69. | 0 | غير مباشرة (I) See Footnote | لا | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| فتح الإيداع 0001104659-25-123156 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 17 ديسمبر 2025 أُودع في 19 ديسمبر 2025 | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) ورقة مالية مشتقة: Amended Series C Common Stock Purchase Warrants — الأصل الأساسي Common Stock (250,627) — سعر الممارسة 0.01 | مُتصرَّف فيه (D) | 250,627 | 10.99 | 2,754,390.73 مشتق: الأسهم × سعر السهم. القيمة الدقيقة 2754390.73. | 0 | غير مباشرة (I) See Footnote | لا | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| فتح الإيداع 0001104659-25-123156 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 17 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | Hill Malcolm R Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (1,218) — سعر الممارسة 5.41 | مُتصرَّف فيه (D) | 1,218 | — | — | 0 | مباشرة (D) | لا | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| فتح الإيداع 0001193125-25-322642 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 17 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | Hill Malcolm R Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (5,833) — سعر الممارسة 4.45 | مُتصرَّف فيه (D) | 5,833 | — | — | 0 | مباشرة (D) | لا | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| فتح الإيداع 0001193125-25-322642 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 17 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | Hill Malcolm R Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (1,218) — سعر الممارسة 3.453 | مُتصرَّف فيه (D) | 1,218 | — | — | 0 | مباشرة (D) | لا | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| فتح الإيداع 0001193125-25-322642 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 17 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | GARNER CAM L Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (1,479) — سعر الممارسة 5.41 | مُتصرَّف فيه (D) | 1,479 | — | — | 0 | مباشرة (D) | لا | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| فتح الإيداع 0001193125-25-322643 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 17 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | GARNER CAM L Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (8,750) — سعر الممارسة 4.45 | مُتصرَّف فيه (D) | 8,750 | — | — | 0 | مباشرة (D) | لا | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| فتح الإيداع 0001193125-25-322643 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 17 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | GARNER CAM L Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (1,291) — سعر الممارسة 3.453 | مُتصرَّف فيه (D) | 1,291 | — | — | 0 | مباشرة (D) | لا | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| فتح الإيداع 0001193125-25-322643 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 17 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | WIDDER KENNETH J Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (1,187) — سعر الممارسة 5.41 | مُتصرَّف فيه (D) | 1,187 | — | — | 0 | مباشرة (D) | لا | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| فتح الإيداع 0001193125-25-322641 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 17 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | WIDDER KENNETH J Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (5,833) — سعر الممارسة 4.45 | مُتصرَّف فيه (D) | 5,833 | — | — | 0 | مباشرة (D) | لا | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| فتح الإيداع 0001193125-25-322641 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 17 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | WIDDER KENNETH J Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (1,187) — سعر الممارسة 3.453 | مُتصرَّف فيه (D) | 1,187 | — | — | 0 | مباشرة (D) | لا | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| فتح الإيداع 0001193125-25-322641 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 17 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | REED VICKIE S Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (1,250) — سعر الممارسة 5.41 | مُتصرَّف فيه (D) | 1,250 | — | — | 0 | مباشرة (D) | لا | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| فتح الإيداع 0001193125-25-322638 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 17 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | REED VICKIE S Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (5,833) — سعر الممارسة 4.45 | مُتصرَّف فيه (D) | 5,833 | — | — | 0 | مباشرة (D) | لا | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| فتح الإيداع 0001193125-25-322638 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 17 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | REED VICKIE S Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (1,250) — سعر الممارسة 3.453 | مُتصرَّف فيه (D) | 1,250 | — | — | 0 | مباشرة (D) | لا | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| فتح الإيداع 0001193125-25-322638 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 17 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | Brady Todd C Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (1,218) — سعر الممارسة 5.41 | مُتصرَّف فيه (D) | 1,218 | — | — | 0 | مباشرة (D) | لا | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| فتح الإيداع 0001193125-25-322639 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 17 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | Brady Todd C Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (5,833) — سعر الممارسة 4.45 | مُتصرَّف فيه (D) | 5,833 | — | — | 0 | مباشرة (D) | لا | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| فتح الإيداع 0001193125-25-322639 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 17 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | Brady Todd C Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (1,187) — سعر الممارسة 3.453 | مُتصرَّف فيه (D) | 1,187 | — | — | 0 | مباشرة (D) | لا | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| فتح الإيداع 0001193125-25-322639 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 17 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | Smeal Benjamin C. Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (5,833) — سعر الممارسة 5.51 | مُتصرَّف فيه (D) | 5,833 | — | — | 0 | مباشرة (D) | لا | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| فتح الإيداع 0001193125-25-322645 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 17 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | Smeal Benjamin C. Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (1,125) — سعر الممارسة 3.453 | مُتصرَّف فيه (D) | 1,125 | — | — | 0 | مباشرة (D) | لا | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| فتح الإيداع 0001193125-25-322645 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 17 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | CARLSON MARILYN R. Officer: Chief Medical Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (17,291) — سعر الممارسة 5.27 | مُتصرَّف فيه (D) | 17,291 | — | — | 0 | مباشرة (D) | لا | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| فتح الإيداع 0001193125-25-322644 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 17 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | CARLSON MARILYN R. Officer: Chief Medical Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (11,000) — سعر الممارسة 4.45 | مُتصرَّف فيه (D) | 11,000 | — | — | 0 | مباشرة (D) | لا | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| فتح الإيداع 0001193125-25-322644 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 17 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | D'Onofrio Matthew J Director · Officer: Chief Executive Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (64,840) — سعر الممارسة 5.27 | مُتصرَّف فيه (D) | 64,840 | — | — | 0 | مباشرة (D) | لا | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| فتح الإيداع 0001193125-25-322637 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 17 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | D'Onofrio Matthew J Director · Officer: Chief Executive Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (70,000) — سعر الممارسة 4.45 | مُتصرَّف فيه (D) | 70,000 | — | — | 0 | مباشرة (D) | لا | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| فتح الإيداع 0001193125-25-322637 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 17 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | Kowieski Mark Officer: Chief Financial Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (17,291) — سعر الممارسة 5.27 | مُتصرَّف فيه (D) | 17,291 | — | — | 0 | مباشرة (D) | لا | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| فتح الإيداع 0001193125-25-322640 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 17 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | Kowieski Mark Officer: Chief Financial Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (13,000) — سعر الممارسة 4.45 | مُتصرَّف فيه (D) | 13,000 | — | — | 0 | مباشرة (D) | لا | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| فتح الإيداع 0001193125-25-322640 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 17 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | PYSZCZYMUKA GREG Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (5,833) — سعر الممارسة 5.26 | مُتصرَّف فيه (D) | 5,833 | — | — | 0 | مباشرة (D) | لا | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| فتح الإيداع 0001193125-25-322646 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 17 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | PYSZCZYMUKA GREG Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (1,155) — سعر الممارسة 3.453 | مُتصرَّف فيه (D) | 1,155 | — | — | 0 | مباشرة (D) | لا | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| فتح الإيداع 0001193125-25-322646 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 16 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | Hill Malcolm R Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | مُتصرَّف فيه (D) | 133 | — | — | 0 | مباشرة (D) | لا | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| فتح الإيداع 0001193125-25-322642 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 16 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | GARNER CAM L Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | مُتصرَّف فيه (D) | 2,330 | — | — | 0 | غير مباشرة (I) By Garner Investments, L.L.C. | لا | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| فتح الإيداع 0001193125-25-322643 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 16 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | Brady Todd C Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | مُتصرَّف فيه (D) | 27 | — | — | 0 | مباشرة (D) | لا | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| فتح الإيداع 0001193125-25-322639 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 16 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | CARLSON MARILYN R. Officer: Chief Medical Officer | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | مُتصرَّف فيه (D) | 360 | — | — | 0 | مباشرة (D) | لا | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| فتح الإيداع 0001193125-25-322644 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 16 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | D'Onofrio Matthew J Director · Officer: Chief Executive Officer | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | مُتصرَّف فيه (D) | 15,509 | — | — | 0 | مباشرة (D) | لا | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| فتح الإيداع 0001193125-25-322637 مقروء من XML الإيداع الاعتراض على هذا الصف |
| 16 ديسمبر 2025 أُودع في 17 ديسمبر 2025 | Kowieski Mark Officer: Chief Financial Officer | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | مُتصرَّف فيه (D) | 11,815 | — | — | 0 | مباشرة (D) | لا | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| فتح الإيداع 0001193125-25-322640 مقروء من XML الإيداع الاعتراض على هذا الصف |